{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:58:19Z","timestamp":1783382299921,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.ygyno.2012.06.028","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T08:29:17Z","timestamp":1340785757000},"page":"141-146","source":"Crossref","is-referenced-by-count":88,"title":["Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva"],"prefix":"10.1016","volume":"127","clinical-trial-number":[{"clinical-trial-number":"nct00476476","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"N.S.","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.B.","family":"Growdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.N.","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2012.06.028_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer Statistics 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ygyno.2007.11.011","article-title":"Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States","volume":"108","author":"Stroup","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.06.028_bb0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0360-3016(98)00193-X","article-title":"Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group","volume":"42","author":"Moore","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ygyno.2012.06.028_bb0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ygyno.2005.03.006","article-title":"Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva","volume":"97","author":"Gonzales","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/1097-0142(20000701)89:1<116::AID-CNCR16>3.0.CO;2-4","article-title":"Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF study","volume":"89","author":"Maggino","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2012.06.028_bb0030","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/annonc\/mdp043","article-title":"Phase II study of paclitaxel in patients with recurrent, metastatic, or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCC","volume":"20","author":"Witteveen","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0035","first-page":"457","article-title":"Psychosexual adjustments after vulvar surgery","volume":"62","author":"Andersen","year":"1983","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.ygyno.2012.06.028_bb0040","first-page":"336","article-title":"Surgical treatment of early-stage vulva carcinoma and the complications of the operation","volume":"149","author":"de Hullu","year":"2005","journal-title":"Ned Tijdshr Geneeskd"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0045","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0050","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1582-4934.2008.00298.x","article-title":"Epidermal growth factor receptor and cancer: control of oncogenic signaling by endocytosis","volume":"12","author":"Grandal","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0055","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0060","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","article-title":"Epidermal growth factor receptor mutations in non small cell lung cancer: Implications for treatment and tumor biology","volume":"23","author":"Janne","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0065","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2007.14.0111","article-title":"Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non small cell lung cancer patients treated with cetuximab and chemotherapy","volume":"26","author":"Hirsch","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0075","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1200\/JCO.2006.07.2587","article-title":"Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas","volume":"24","author":"Chung","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0080","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/annonc\/mdm003","article-title":"Combination of EGFR gene copy number and protein expression predicts outcome for advanced non small cell lung cancer patients treated with gefitinib","volume":"18","author":"Hirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0085","doi-asserted-by":"crossref","first-page":"411s","DOI":"10.1200\/jco.2009.27.15_suppl.8020","article-title":"Biomarker analyses form the phase III placebo-controlled SATURN study of maintenance erlotinib following first line chemotherapy for advanced NSCLC","volume":"27","author":"Brugger","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2012.06.028_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.lungcan.2008.02.008","article-title":"EGFR FISH versus mutation: different tests, different endpoints","volume":"60","author":"Cappuzzo","year":"2008","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2012.06.028_bb0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/gyno.1997.4660","article-title":"Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival","volume":"65","author":"Johnson","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.06.028_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2006.07.035","article-title":"EGFR expression is associated with groin node metastases in vulvar cancer but does not improve their prediction","volume":"104","author":"Oonk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0105","first-page":"381","article-title":"Expression of epidermal growth factor receptor and HER-2\/new in normal and neoplastic cervix, vulva, and vagina","volume":"76","author":"Berchuck","year":"1990","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2008.07.038","article-title":"Decreased survival in EGFR gene amplified vulvar carcinoma","volume":"111","author":"Growdon","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0115","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2007.05.006","article-title":"Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva","volume":"106","author":"Olawaiye","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2012.06.028_bb0120","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1525-1438.2007.01145.x","article-title":"Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab","volume":"18","author":"Richard","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2012.06.028_bb0125","first-page":"423","article-title":"A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor","volume":"32","author":"Bacha","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0130","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/pgp.0b013e3180555999","article-title":"Epidermal growth factor receptor is involved in the development of an invasive phenotype of vulvar squamous lesions but is not related to MIB-1 immunoreactivity","volume":"26","author":"Brustman","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0135","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2005.09.111","article-title":"Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor positive non small cell lung cancer patients","volume":"23","author":"Cappuzzo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0140","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1200\/JCO.2007.14.8494","article-title":"First line gefitinib in advanced non small cell lung cancer patients harboring somatic EGFR mutations","volume":"26","author":"Sequist","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1 Suppl.","key":"10.1016\/j.ygyno.2012.06.028_bb0145","first-page":"13s","article-title":"Adriamycin treatment of advanced vulvar cancer","volume":"50","author":"Deppe","year":"1977","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000421-198904000-00011","article-title":"Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma: a Gynecologic Oncology Group study","volume":"12","author":"Muss","year":"1989","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2012.06.028_bb0155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000259259","article-title":"Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma","volume":"77","author":"Cormio","year":"2009","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ygyno.2012.06.028_bb0160","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/gyno.2001.6180","article-title":"Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous cell carcinoma or the vulva: an EORTC Gynecological Cancer Cooperative Group study","volume":"81","author":"Wagenaar","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"4\u20135","key":"10.1016\/j.ygyno.2012.06.028_bb0165","first-page":"639","article-title":"Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva","volume":"64","author":"Trope","year":"1980","journal-title":"Cancer Treat Rep"},{"issue":"3","key":"10.1016\/j.ygyno.2012.06.028_bb0170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0090-8258(86)90138-1","article-title":"Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group study","volume":"23","author":"Thigpen","year":"1986","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2012.06.028_bb0175","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-08-0093","article-title":"Reduced erlotinib sensitivity of epidermal growth factor receptor mutant non small cell lung cancer following cisplatin exposure: a cell culture model of second line erlotinib treatment","volume":"14","author":"Chin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0180","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/annonc\/mdp520","article-title":"A multicenter phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non small cell lung cancer","volume":"21","author":"Tan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0185","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.109.062117","article-title":"Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer","volume":"50","author":"Mishani","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ygyno.2012.06.028_bb0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of Megestrol Acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812004799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825812004799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T15:45:12Z","timestamp":1642607112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825812004799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0090825812004799"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.06.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}